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ABSTRACT  
This study investigates the effect of adiponectin on endothelial activation and inflammatory 
marker secretion by human coronary artery endothelial cells (HCEAC) in vitro.  
Methodology: HCAEC at the seventh passage were divided into two groups and incubated for 
24 hours at 37° C and 5% CO2 as follows: Control, and adiponectin-treated (30 µg/ml 
adiponectin) groups.  Supernatants were analysed for ICAM-1, E-selectin, PAI-1 and IL-6 and 
COX-2 using ELISA.  RT-PCR was used to analyse gene expression of ICAM-1, E-selectin, 
PAI-, IL-6, COX-2, NFkBp50 and NFkBp65. Data were analysed using independent t-test.  
Results: ICAM-1 and E-selectin level was significantly higher in leptin-adiponectin-treated 
groups (P<0.01).  Endothelial activation marker protein level have no significant difference in 
adiponectin group when compared to control group.   
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mRNA expression showed significant increase in adiponectin group as compared to control. 
PAI-1 and COX-2 showed no significant increase in the level of protein in adiponectin group 
but IL-6 showed significant increased in the protein level (P<0.001) while mRNA expression of 
PAI-1 (P<0.05), COX-2 (P<0.01) and IL-6 (P<0.001) showed significant increase in treated 
group as compared to control.  mRNA expression also showed significant increase in both the 
NFkBp50 and NFkBp65 signalling pathway.   
Conclusion: Adiponectin increases the secretion of IL-6 from HCEAC.  This adipokines 
might have a significant role in the inflammatory and pro-atherogenic state of obesity. 
Keywords: HCAEC, Adiponectin, ICAM-1, E-selectin, IL-6, PAI-1, COX-2, NFkB. 
 
1. INTRODUCTION 
Adipose tissue has been shown to secrete bioactive substances (adipokines) that influence 
endothelial function [1-3]. Although the precise link between cardiovascular morbidity and 
adipokines remains unclear, a low inflammatory state with generalized endothelial activation is 
believed to underlie the risk for diseases like hypertension, atherosclerosis and ischaemic heart 
disease.  Much, however, remains to be examined on the link between adipokines and 
cardiovascular diseases.  Adipose tissue secretes a variety of bioactive molecules that might 
directly contribute to the low inflammatory state and development of cardiovascular diseases 
like atherosclerosis [4].  One of the earliest events in atherosclerosis is the recruitment and 
binding of circulating leukocytes to the vascular endothelium.  Then, further movement of 
leukocytes into the sub-endothelial spaces during development of atherosclerosis is facilitated 
through cellular adhesion molecules  Atherosclerosis Risk In Communities (ARIC) study 
found a significant link between circulating vascular cell adhesion molecule-1 (VCAM-1), 
endothelial-leukocyte adhesion molecule-1 (E-selectin), intercellular adhesion molecule-1 
(ICAM-1) and the degree of atherosclerosis as identified by B-mode ultrasound [5, 6]. 
Adiponectin levels are reduced in obesity [1].  Adiponectin, a 30 kDa plasma protein 
secreted by adipose tissue correlates negatively with percentage of body fat, waist to hip ratio 
and intra-abdominal fat [7-9].  Plasma adiponectin concentrations are lower in patients with 
clinical symptoms of coronary artery disease than in age- and BMI-adjusted control subjects 
[10, 11].  Adiponectin has been reported to have an anti-atherogenic effect, as in cultured 
N. A. Rosman et al.            J Fundam Appl Sci. 2017, 9(6S), 1102-1115         1104 
 
cells human recombinant adiponectin was found to suppress the endothelial expression of 
adhesion molecules, the proliferation of smooth muscle cells and the transformation of 
macrophage to foam cells [10].   
Many different signalling pathways are involved in the progression of inflammatory response. 
This inflammatory state has been proposed to be a contributing factor between obesity and 
cardiovascular diseases [12]. NFkB has been indicated to influence numerous cardiovascular 
diseases [12] and NFkB transcription factors are one of the distinguished components that 
regulate genes engaged in the inflammatory process [13]. Endothelial cells activation and 
expression are controlled by NFkB signalling [14]. 
Whilst numerous reports exist on the effect of leptin and adiponectin on endothelial function 
little is known about the interaction between leptin and adiponectin together on endothelial 
cell function.  It is unclear if adiponectin antagonises the actions of leptin on the 
endothelium.  This study therefore investigates the effect of leptin and adiponectin on 
ICAM-1, E-selectin, PAI-1 and IL-6 and COX-2 secretion by human coronary artery 
endothelial cells (HCAEC) in vitro. 
 
2. METHODOLOGY 
Human coronary artery endothelial cells (HCAEC) (Lonza, USA), at the seventh passage, were 
cultured in 12 T75 flasks at 37°C and 5% CO2 in endothelial growth media-2 (EGM-2, Lonza, 
USA) supplemented with 5% FBS,  0.04% hydrocortisone, 0.4% hFGF-B, 0.1% VEGF, 0.1% 
R3-IGF-1, 0.1% ascorbic acid, 0.1% hEGF  and 0.1% GA-1000) with >90% purity (by SDS 
PAGE) until 80% confluent.  The flasks with the cultured cells were then divided into two 
groups with 3 flasks in each group and incubated for 24 hours as follows: Control and 
adiponectin-treated (30 µg/ml Human Recombinant Adiponectin - Biovision) groups.   After 
24 hours of incubation the cells were detached from the flasks using accutase and the cell 
suspension was centrifuged for 5 minutes at 220g.  The supernatants were analysed for 
ICAM-1, E-selectin, PAI-1 and IL-6 and COX-2 using commercially available ELISA kits 
(eBioscience) whilst the cell lysate was used for the extraction of mRNA and expression 
studies.  The concentrations of these in the supernatants were standardised for the cell counts 
and expressed as percentage of the controls. 
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Real time RNA analyses were performed to determine the effect of leptin and adiponectin 
treatment on ICAM-1, E-selectin, IL-6 and COX-2 transcription and also NFkBp50 and 
NFkBp65.  Total RNA was extracted from the treated cells using AllPrep RNA/Protein kit 
(Qiagen, Germany).   Reverse transcription was performed from 30 ng of RNA using 
iScript™ cDNA Synthesis Kit (BIO-RAD, CA).  The cDNA templates (1 µl) were added per 
10 µl reaction with sequence specific primers of ICAM-1, E-selectin, IL-6 transcription in 
treated cells.  All target gene primers were purchased from AIT Biotech (Singapore).  For the 
analysis of ICAM-1, forward primer 5’-ATGCCCAGACATCTGTGTCC-3’ and reverse 5’- 
GGGGTCTCTATGCCCAACAA-3’ were used.  For the E-selectin, forward primer 
5’-CAGCAAAGGTACACACACCTG-3’ and reverse 
5’-CAGACCCACACATTGTTGACTT-3’ were used.  For IL-6, the forward primer 5’ 
ACTCACCTCTTCAGAACGAATTG-3’ and the reverse primer 5’ 
CCATCTTTGGAAGGTTCAGGTTG-3’ were used. The forward primer for PAI-1 was 5’- 
CCTGGGCACTTACAGGAAGG-3’ while reverse primer was 5’- 
GGTCCGATTCGTCGTCAAATAAC-3’. For COX-2, the forward and reverse primers were 
5’- CCAGTATAAGTGCGATTGTACCC-3’ and 5’- TCAAAAATTCCGGTGTTGAGCA-3’ 
respectively.  The forward primer for NFkBp50 was 5’-AACCTGCAGCAGACTCCACT-3’ 
and reverse 5’-ACACCAGGTCAGGATTTTGC-3’ while forward primer for NFkBp65 was 
5’-TCAATGGCTACACAGGACCA-3’ and reverse was 
5’-CACTCTCACCTGGAAGCAGA-3’.  For GAPDH 5’-CTGGGCTACACTGAGCACC-3’ 
and 5’-AAGTGGTCGTTGAGGGCAATG-3’ were used as forward and reverse primers 
respectively and for HPRT-1  the forward and reverse primers were 
5’-CCTGGCGTCGTGATTAGTGAT-3’ and 5’- AGACGTTCAGTCCTGTCCATAA-3’ 
respectively. These were used as reference genes. Assays were carried out in triplicate using 
CFX96 version 2.1 (BIO-RAD, CA).  Amplification curves for ICAM-1; E-selectin and IL-6, 
PAI-1 and COX-2 were produced with an initial denaturing step at 95°C for 30 sec, followed by 
40 cycles at 95° C for 5 sec and 60°C for 10 s.  Amplification curves for NFkB were generated 
with an initial step of denaturing at 3 min, followed by 50 cycles at 95°C for 10 s and 60°C for 
45 s.  Reactions were normalized to copies of GAPDH and HPRT-mRNA within the same 
sample using -∆∆CT method. Results are expressed as fold increases compared to control.  
N. A. Rosman et al.            J Fundam Appl Sci. 2017, 9(6S), 1102-1115         1106 
 
Data are presented as mean ± SEM.  Data were analysed using independent sample t-test, with 
level of significance set at p< 0.05. 
 
Table 1. Primer Sequence for Housekeeping Gene, Markers of Inflammation and Endothelial 
Activation 
Housekeeping 
GAPDH F 5’-CTGGGCTACACTGAGCACC-3’ 
 R 5’-AAGTGGTCGTTGAGGGCAATG-3’ 
HPRT-1 F 5’-CCTGGCGTCGTGATTAGTGAT-3’ 
 R 5’-AGACGTTCAGTCCTGTCCATAA-3’ 
Markers of Inflammation 
IL-6 F 5’-ACTCACCTCTTCAGAACGAATTG-3’ 
 R 5’-CCATCTTTGGAAGGTTCAGGTTG-3’ 
PAI-1 F 5’-CCTGGGCACTTACAGGAAGG-3’ 
 R 5’-GGTCCGATTCGTCGTCAAATAAC-3’ 
COX-2 F 5’-CCAGTATAAGTGCGATTGTACCC-3’ 
 R 5’-TCAAAAATTCCGGTGTTGAGCA-3’ 
NFkBp50 F 5’-AACCTGCAGCAGACTCCACT-3’ 
 R 5’-ACACCAGGTCAGGATTTTGC-3’ 
NFkBp65 F 5’-TCAATGGCTACACAGGACCA-3’ 
 R 5’-CACTCTCACCTGGAAGCAGA-3’ 
Markers of Endothelial Activation 
ICAM-1 F 5’-ATGCCCAGACATCTGTGTCC-3’ 
 R 5’-GGGGTCTCTATGCCCAACAA-3’ 
E-selectin F 5’-CAGCAAAGGTACACACACCTG-3’ 
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3. RESULTS 
3.1 Endothelial Activation Marker 
Table 2. Soluble ICAM-1 and E-selectin concentrations in the supernatants expressed as 
percentage of control 
 C A 
ICAM-1 100+4.19 108.02+8.90 
E-selectin 100+ 4.35 115.66+9.70 
 
Table 2 presents ICAM-1 protein concentrations in the supernatants after 24 hours of 
incubation with and without adiponectin, expressed as percentage of the control.  ICAM-1 





The ICAM-1 mRNA expression in adiponectin treated group was significantly higher when 
compared to that in the control, (P<0.001; Figure 1).   
 
Figure 1: ICAM-1 mRNA expression (Fold increase)   
***P < 0.001; compared to control 
*** 





The E-selectin mRNA expression in adiponectin treated group was significantly higher than 
that in the control groups (P<0.001; Figure 2). 
 
3.2 Inflammation Marker 
Table 3. Soluble PAI-1, IL-6 and COX-2 protein concentration in supernatants expressed as 
percentage of control 
 C A 
PAI-1 100+23.20 117.64+19.90 
IL-6 100+23.20 761.95+94.00*** 
COX-2 100+28.70 193.93+36.34 
***P < 0.001; compared to Control 
 
PAI-1 and COX-2 protein levels in the supernatant of adiponectin treated groups have no 
significance difference than those of control.  On the other hand, IL-6 was found to be 
significantly higher in the treated group (P<0.001; Table 2).   
 
Figure 2: E-selectin mRNA expression (Fold increase)   
 
***P < 0.001; compared to Control 
*** 






The mRNA expression of IL-6 expression in the adiponectin group was significantly higher 







Figure 3: IL-6 mRNA expression (Fold Increase) 
 
***
P<0.001; compared to Control 
Fig.4: PAI-1 mRNA expression (Fold Increase) 
*
P<0.05; compared to Control 
* 
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PAI-1 mRNA expression in the adiponectin group was found to be significantly higher than 






COX-2 mRNA expression in the adiponectin group was significantly higher than that in the 










Figure 5: COX-2 mRNA expression (Fold Increase) 
 
**
P<0.01; compared to Control 
** 






Both NFkBp50 and NFkBp65 expression were found to be significantly higher in adiponectin 
treated group (P<0.001), when compared to that in the controls.  
 
4. DISCUSSION 
The major findings of this study are that (i) adiponectin significantly increased the levels of 
IL-6 protein secretion in cultured HCAEC, and (ii) adiponectin independently up-regulated the 
expression of ICAM-1, E-selectin, PAI-1, IL-6, COX-2, NFkBp50 and NFkBp65 mRNA in 
human coronary artery endothelial cells.    
Endothelial dysfunction is characterized with a few changes that the endothelium undertakes 
during the proses of atherogenesis. These includes i) damage to the anticoagulant properties of 
the endothelium, ii) increased expression of the cellular adhesion molecules and iii) loss of 
bioavailability of vasodilatory  endothelial nitric oxide.  Obesity is characterized as chronic 
low-grade inflammatory, and adiponectin level is decreased in obesity indicating dysregulation 
of adiponectin could be applicable to obesity-linked disorder.  In the early phases of 
atherosclerosis endothelial cell activation by numerous inflammatory stimuli will results in the 
synthesis of adhesion molecules [15]. Adiponectin is an adipocyte-specific plasma protein 
which regulates inflammatory stimuli in endothelial cells endogenously [11]. The effect of 
Figure 6: NFkBp50 and NFkBp65 mRNA expression (Fold increase) 
***P < 0.001; compared to Control 
*** 
*** 
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adiponectin on endothelial cells in culture has been reported before, in which adiponectin (50 
ug//mL) treatment alone did not indicate any significant modifications in the surface expression 
of ICAM-1 and E-selectin in human aortic endothelial cells (HAEC) [11]. The mRNA 
expression of adhesion molecules however was done by using Northern Blot analysis and no 
significant difference was found in HAECs that was18 hours pre-treated with adiponectin. 
Plasminogen activator inhibitor 1 (PAI-1) is the major inhibitor of plasminogen in vivo and 
increased PAI-1 in plasma will interfere the mechanism of fibrin clearance hence encourage 
thrombosis [16].  PAI-1 is noticeably elevated in obesity and associated with increased risk of 
certain diseases such as atherosclerosis, myocardial infarction and hypertension. In this study 
we demonstrated that the soluble protein concentration of PAI-1 has no significance difference 
between untreated HCAEC as compared with adiponectin treated cells. However, the mRNA 
expression of PAI-1 was significantly increased by 1.8 fold in the treated group. It was 
observed that significant improvements in PAI-1 plasma level were evident in patients after 1 
year of weight loss therapy in both metabolic syndrome and non-metabolic syndrome groups. It 
was also evident that the level of adiponectin, which was identified as an anti-inflammatory 
cytokine did not increased significantly post-therapy in the metabolic syndrome group [17]. 
IL-6 was defined as proinflammatory cytokine and synthesized by a range of tissues such as 
adipocytes, stimulated leucocytes and also endothelial cells.  Several studies demonstrated that 
the level of IL-6 in the plasma is notably elevated in condition of insulin resistance and obesity 
[18-20]. In this study both the soluble protein concentration of IL-6 and gene expression in 
cultured HCAEC showed significant increase in the adiponectin treated group as compared to 
non-treated cells with the mRNA expression showed 2-fold increased.   
It was stated that adiponectin protects the heart from numerous damages [21].  Myocardial 
ischemia-reperfusion injury was prevented through AMPK- and COX-2-dependent 
mechanisms [22]. This study showed marked increase in the mRNA expression of COX-2 by 
13-fold even though the translation of protein does not show significant difference. Study 
showed that adiponectin increases COX-2 expression in primary neonatal rat ventricular 
cardiac myocytes treated with 30 ug/mL adiponectin and incubated for 18 hours [23]. 
NFkB has long been acknowledged as a pro-inflammatory signaling pathway, in which the 
activation of NFkB is through the commencement of pro-inflammatory cytokines, chemokines 
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and adhesion molecules [24].  Activation of NFkB normally will cause the up-regulation of 
anti-apoptotic genes thus enabling the cells to bear stresses elicited during the progression of 
inflammation.  NFkB also stimulate cytokine as well as adhesion molecules which result in the 
leucocyte engagement to the inflamed area.  In this study, NFkBp50 was found to be 
significantly up-regulated in adiponectin treated (P<0.001) group as compared to control. 
Meanwhile, NFkBp65 significantly increased in the mRNA expression in adiponectin 
treatment compared to control (P<0.001) group.  Homodimers of the p50 NFkB subunit with 
deficient of transactivation domains have been indicated to inhibit expression of NFkB target 
genes and inhibit inflammation [25].  These findings may suggest comprehensive role of 
well-labelled pro- and anti-atherosclerotic property of adiponectin. 
 
5. CONCLUSION 
Adiponectin increases the expression of ICAM-1, E-selectin, IL-6, PAI-1, COX-2, NFkBp50 
and also NFkBp65 from HCEAC.  This adipokines might have a significant role in the 
inflammatory and pro-atherogenic state of obesity. 
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